2U11/158249 Al
Total Page:16
File Type:pdf, Size:1020Kb
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date \ / ; 22 December 2011 (22.12.2011) 2U1n 1/158249ft Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 209/48 (2006.01) C07C 231/12 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 307/93 (2006.01) C07C 237/24 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/IN20 11/000387 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, June 201 1 (09.06.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1809/MUM/2010 16 June 2010 (16.06.2010) IN kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): GLEN- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, MARK GENERICS LIMITED [IN/IN]; Glenmark TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, House, HDO- Corporate Bldg, Wing-A, B. D. Sawant EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, Marg, Chakala, Andheri (East), Mumbai 400099 (IN). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventors; and GW, ML, MR, NE, SN, TD, TG). (75) Inventors/ Applicants (for US only): JAMBUKAR, Nagambar Genuji [IN/IN]; Flat No. A/401, Lenaydri Declarations under Rule 4.17 : Park CHSL, Adharwdi Chowk, Kalyan (West), Thane — as to applicant's entitlement to apply for and be granted 421301, Maharashtra (IN). GHARPURE, Milind a patent (Rule 4.1 7(H)) [IN/IN]; Flat No. C-401, Patel heights, Sector-7, Ghan- soli, Navi Mumbai 400709, Maharashtra (IN). SINARE, — of inventorship (Rule 4.1 7(iv)) Sudani Nanabhau [IN/IN]; Shantidut Apartment, Published: AL5 11917, Sector-5, Airoli, Navi Mumbai 400708, M a harashtra (IN). THOMBRE, Pravin Chhaburao — with international search report (Art. 21(3)) [IN/IN]; D002, Chandresh Park CHS, Deslepada, Near — before the expiration of the time limit for amending the Ganesh Mandir, Dombivili (East), Thane 421201, Mah a claims and to be republished in the event of receipt of rashtra (IN). KHAN, Mubeen Ahmed [IN/IN]; H2-0: l , amendments (Rule 48.2(h)) Panchdeep Society, Sector-29, Vashi, 400 703 Navi Mumbai, Maharashtra, (IN). (54) Title: PROCESS FOR PREPARATION OF MILNACIPRAN INTERMEDIATE AND ITS USE IN PREPARATION OF PURE MILNACIPRAN v (57) Abstract: Disclosed is a process for the preparation of milnacipran intermediate, a compound of formula III, and its use in the preparation of pure milnacipran. PROCESS FOR PREPARATION OF MILNACIPRAN INTERMEDIATE AND ITS USE IN PREPARATION OF PURE MILNACIPRAN PRIORITY [0001] This application claims the benefit to Indian Provisional Application No. 809/MUM/2010, filed on June 16, 2010, and entitled "PROCESS FOR PREPARATION OF MILNACIPRAN INTERMEDIATE AND ITS USE IN PREPARATION OF PURE MILNACIPRAN", which is incorporated herein by reference. BACKGROUND OF THE INVENTION Technical Field [0002] The present invention relates to a process for the preparation of a compound cis-(±)-2-[(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)methyl]-N,N-diethyl-l- phenylcyclopropane carboxamide and/or its pharmaceutically acceptable salts and its conversion to milnacipran. Description of the Related Art [0003] Milnacipran, also known as (±)-[lR(S), 2S(R)]-2-(aminomethyl)-N,N- diethyl-l-phenylcyclopropanecarboxamide, is represented by the structure of formula II: [0004] Milnacipran hydrochloride, formula I, a selective norepinephrine and serotonin reuptake inhibitor, is found useful in the treatment of depression and chronic pain conditions like fibromyalgia syndrome and lupus. Milnacipran hydrochloride inhibits norepinephrine uptake with greater potency than serotonin. Milnacipran hydrochloride is marketed in the United States under the brand name Savella® in the form of 12.5, 25. 50 and 100 mg tablets for fibromyalgia syndrome; while in Europe, it is available under the brand name Ixel® in the form of 25, 50 and 100 mg tablets for depression. l 10005] U.S. Patent No. 4,478,836 ("the '836 patent") discloses milnacipran and its hydrochloride salt form. The '836 patent discloses a process for the preparation of milnacipran hydrochloride by the reaction of an acid chloride of cis- 1-phenyl- 1- ethoxycarbonyl-2-aminomethylcyclopropane with diethylamine and salifying with hydrochloric acid. The rocess is schematically represented b scheme I : [0006] Patent Publication WO2008/1 04957 (the '957 publication) discloses a multistep process for the preparation of milnacipran hydrochloride by the reaction of (Z)- l-phenyl-l-diethylaminocarbonyl-2-phthalimidomethylcyclopropane of formula III with hydrazine hydrate and the resultant milnacipran product isolated as a wet compound with a significant amount of phthalimide by-products, which are removed by acid-base treatment and whereupon the milnacipran is directly converted to its hydrochloride salt form. The process disclosed in the '957 publication is schematically represented by scheme II: (III) Milnacipran hydrochloride Scheme II [0007] U.S. Patent No. 5,034,541 ("the '541 patent") discloses a process for preparation ofmilnacipran intermediate, cis-(±)-2-[(l,3-dioxo-l,3-dihydro-2H-isoindol-2- yl)methyl]-N,N-diethyl-l-phenylcyclopropanecarboxamide of compound of formula III. The process comprises opening the cis-(±)-l-phenyl-3-oxabicyclo[3.1.0]hexan-2-one of formula VI using diethylamine with the aid of a Lewis acid, converting the cis-(±)-l- phenyl-l-diethylaminocarbonyl-2-hydroxymethylcyclopropane of formula V resulting into its 2-chloro derivative of formula IV by the action of a chlorination reagent, then the 2-chloro derivative is converted into the compound of formula III by reaction with a phthalimide salt at 110°C. [0008] The final step of the '541 patent process was carried out at high temperature; which may have led to formation of impurities in milnacipran. The process disclosed in the '541 patent is schematically represented by scheme III: S che III [0009] Impurities in milnacipran or any active pharmaceutical ingredient (API) are undesirable and, in extreme cases, might even be harmful to a patient being treated with a dosage form containing the API. [0010] It is also known in the art that impurities in an API may arise from degradation of the API itself, which is related to the stability of the pure API during storage, and the manufacturing process, including the chemical synthesis. Process impurities include unreacted starting materials, chemical derivatives of impurities contained in starting material, synthetic by-products, and degradation products. [0011] The purity of the API produced in the commercial manufacturing process is clearly a necessary condition for commercialization. Impurities introduced during commercial manufacturing processes must be limited to very small amounts, and are preferably substantially absent. For example, the International Conference on Harmonization of Technical Requirements for Registration for Human Use ("ICH") Q7A guidance for API manufacturers requires that process impurities be maintained below set limits by specifying the quality of raw materials, controlling process parameters, like temperature, pressure, time, and stoichiometric ratios, and including purification steps such as washing with water or solvent, crystallization, distillation, and extraction, in the manufacturing process. [0012] Thus there is a need in the art for improved processes for preparing pure milnacipran and its intermediates, which are more industrially applicable. SUMMARY OF THE INVENTION [0013] The present invention is drawn towards the preparation of compounds, that may be used as intermediates in the preparation of milnacipran or its pharmaceutically acceptable salts. The subsequent milnacipran or its pharmaceutical salts contain levels of impurity that render their favorable use as API. [0014] In one aspect , the present invention provides a one-pot process for the preparation of cis-(±)-2-[(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)methyl]-N,N-diethyl- 1-phenylcyclo-propanecarboxamide, a compound of formula III: comprising: a) reacting cis-(±)-l-phenyl-3-oxabicyclo[3.1.0]hexan-2-one, a compound of formula VI with diethylamine in the presence of a Lewis acid and an organic solvent to form cis-i 1-phenyl- 1-diethylaminocarbonyl-2-hydroxymethylcyclopropane, a compound formula V, b) reacting cis-(±)-l -phenyl- l-diethylaminocarbonyl-2-hydroxymethylcyclopropane, the compound of formula V with a chlorinating agent to form cis-(±)-l -phenyl- 1- diethylaminocarbonyl-2-chloromethylcyclopropane, a compound of formula IV and IV c) reacting cis-(±)-l -phenyl- l-diethylaminocarbonyl-2-chloromethylcyclopropane, the compound of formula IV with a phthalimide salt at a temperature range between about 20°C to about 60°C to form the compound of formula III. [0015] In another embodiment, the present invention provides a process for the preparation of cis-(±)-2-[(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)methyl]-N,N-diethyl- 1-phenylcyclo-propanecarboxamide, a compound of formula III, the process comprising, reacting cis-(±)-l -phenyl- 1-diethylaminocarbonyl-2- chloromethylcyclopropane, a compound of formula IV IV with a phthalimide salt, in the presence of an organic solvent at a temperature range between about 20°C to about 60°C.